Atopic Dermatitis

Brian Kim, MD, underscores the critical gap in addressing severe itch in atopic dermatitis, often overshadowed by the visible manifestations of skin rash.

Brian Kim, MD, explores long-term ruxolitinib data and combination therapies in the treatment of pediatric atopic dermatitis.

Christopher Bunick, MD, PhD, expands on how clinicians can personalize treatment plans for each patient.

Christopher Bunick, MD, PhD, reviews benchmarks for optimal outcomes in patients with atopic dermatitis and compares treatments available.

A dermatology expert reviews the role of barrier function in AD and outlines available treatments, emphasizing the importance of moisturizing and rapid options when appropriate, as well as the efficacy of rapid systemic treatments in patients when appropriate.

Alexandra Golant, MD, delves into the prevalence and profound influence of hand and foot involvement in her patients, shedding light on the significant burden it imposes on their quality of life.

Researchers shared details of a noninvasive technique that detects abnormal inflammatory cytokine profiles in the skin of asymptomatic infant patients who subsequently develop AD.

Today officially marks 7 years since the US FDA approved dupilumab for the treatment of atopic dermatitis. Here's a look back at its approval timeline and all it has accomplished in the dermatology world in the time since.

Raj Chovatiya, MD, PhD, dissects the nomenclature of atopic dermatitis and shares the importance of understanding other conditions under the eczema umbrella.

Raj Chovatiya, MD, PhD, gives an overview of what all clinicians need to know about the updated atopic dermatitis guidelines published by the American Academy of Dermatology including approaches with systemic therapies, which therapeutic modalities to prioritize, and patient considerations to guide decision-making.

Late-breaking data demonstrating the sustained improvements was presented at the American Academy of Dermatology Annual Meeting.

Peter Lio, MD, explains the importance of having a wide-range of solutions and how he incorporates alternative approaches alongside conventional medicine.

Peter Lio, MD, expands on dosing considerations to treat atopic dermatitis with involvement on the hands and feet for different ages, weights, lifestyles, and more.

Peter Lio, MD, takes a deep dive into the results of the 3 LIBERTY-AD-HAFT study and how it impacts the treatment of hand-foot atopic dermatitis.

Two recent studies delve into outcomes of pediatric populations with atopic conditions and an overview of patient outcomes utilizing a Mendelian randomization analysis.

Raj Chovatiya, MD, PhD, delves into the conditions that could be red, itchy, and not atopic dermatitis. He explains the importance of knowing characteristics for various inflammatory conditions.

Susan Taylor, MD, explained the current state of diversity in clinical trials, what is going well, and opportunities to improve.

Susan Taylor, MD, shared what she wants to know about patients' functionality to treat their atopic dermatitis with hand or foot involvement.

Burnett recently spoke with Dermatology Times to discuss the background, methods, and findings of the late-breaking INTEGUMENT-PED data, as well as its potential real-world and clinical implications.

Eichenfield discusses the late-breaking data on roflumilast cream 0.05% in the pediatric patient population and its implications.

The international observational study aims to understand how moderate to severe AD affects children under 12 years of age, particularly in terms of height, weight, and BMI.

Lio delves into his American Academy of Dermatology Annual Meeting session, "Dietary Triggers and Modifications of Common Dermatologic Conditions: An Evidence Based Approach."

New data was presented at the American Academy of Dermatology Annual Meeting in San Diego, California.

Alphyn’s first-in-class therapeutic is designed to treat the immune system component, and more specifically the bacterial component, of AD.

In addition to the announcement of positive data, Apogee said the trial has already exceeded its objectives ahead of schedule.

Nitin Joshi, PhD, shared CAGE Bio’s development of CGB-500 and why phase 2 EASI scores have the company’s scientific advisory board optimistic.

Test your knowledge on the AAD's recommendations for phototherapy, monoclonal antibodies, JAK inhibitors, and systemic therapies in the latest guidelines.

Researchers have found Staphylococcus aureus may trigger itchiness in atopic dermatitis, opening the door to new treatment approaches in the future.

Learn more about dupilumab-induced conjunctivitis rates and misconceptions, the thriving long-term efficacy of dupilumab over 3 years, and unraveling the itch-flare dynamic in abrocitinib treatment.

The FDA has also granted nemolizumab Priority Review for prurigo nodularis.